Abbott Laboratories stock holds above $110 as consensus target stays higher
Published on 08/18/2026 at 21:53 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (US0028241000) stock traded a little above $110 as of August 17, 2026, keeping the healthcare group’s market valuation below where it began the year but still backed by a positive analyst consensus on its medium-term prospects. Per a recent market-data overview, the shares closed at $110.68 in New York on August 17, 2026, compared with a starting level of $125.30 at the beginning of 2026, which marks an 11.7% year-to-date decline.
Shares consolidate above the $110 line
Recent trading shows Abbott Laboratories stock hovering modestly below its early-2026 levels but still consolidating above the $110 mark. A detailed stock-analysis page reports that Abbott Laboratories’ stock was trading at $125.30 at the beginning of 2026 and that it is now quoted at $110.68 as of the August 17, 2026 close, representing an 11.7% decrease since the start of the year. The same overview indicates that the closing price of $110.68 on August 17, 2026, reflected a single-session decline of 0.51% for that day.
Beyond the U.S. primary listing, trading data from a euro-denominated venue shows that Abbott Laboratories’ last closing stock price stood at EUR 95.08 on August 17, 2026, with an intraday quote at EUR 95.82 on the next trading day. This translated into a positive short-term performance in that market, with a gain over the prior close captured in the latest table, even as the year-to-date change remained negative. For investors, the divergence between the local-currency performance in euros and the U.S. dollar trajectory underlines how currency exposure affects perceived returns.
Analyst consensus indicates upside to current levels
While the share price sits below its level from the start of 2026, the current analyst consensus still points to potential upside from recent trading levels. A recent institutional-positioning article shows that the consensus rating on Abbott Laboratories is labeled as a “Moderate Buy”, with an average price target of $118.67 based on compiled analyst estimates. Against a latest closing price of $110.68 on August 17, 2026, this average target implies an upside of a little over $8 per share, or roughly 7.2% in percentage terms if achieved.
Several recent filings-focused summaries reiterate this combination of a supportive rating and a target level that remains above the spot price. In each case, the commentary notes that Abbott Laboratories currently carries an average or consensus rating in the positive band, paired with the same consensus target of $118.67. For portfolio managers, that gap between the market price and the consensus objective provides a concrete benchmark when weighing risk and return, especially given the stock’s double-digit percentage decline since the start of 2026.
Dividend and income profile add to the appeal
Income-focused investors also pay attention to Abbott Laboratories’ dividend profile when assessing the stock’s appeal at current levels. A recent quote summary lists a dividend yield of 2.25% based on the current price, together with a payout date of August 17, 2026. Against a closing price of EUR 95.08 cited for the euro-traded line on August 17, 2026, a 2.25% yield signals a cash distribution that can help offset some of the share-price volatility, particularly for long-term holders.
This income element is further supported by the broader framework of the company’s shareholder-return policy, which historically has emphasized regular dividend payments. For investors comparing alternatives in the healthcare sector, a yield in the low single digits combined with a modest implied upside from the consensus price target can make Abbott Laboratories a more balanced proposition than pure growth stories with no dividend support.
Institutional positioning and trading activity
Recent disclosures from various institutional investors highlight active portfolio adjustments involving Abbott Laboratories shares. One filing summary notes that the stock opened at $110.68 on August 18, 2026, in New York trading, describing a modest 0.5% decline relative to the prior session. Similar reports on institutional holdings reductions or additions emphasize that, despite minor day-to-day fluctuations, the stock continues to trade close to the $110 line.
These filings also reiterate the same consensus metrics for Abbott Laboratories, including the “Moderate Buy” rating and the average target price of $118.67. The repetition of these figures across multiple institutional reports underscores that the current market narrative is shaped by a combination of subdued price performance year-to-date and enduring analyst confidence, rather than by a single, dramatic earnings surprise or regulatory event.
Year-to-date performance versus broader context
From a broader perspective, Abbott Laboratories’ share-price trajectory in 2026 blends elements of defensive stability with the drag from its pullback since the start of the year. The 11.7% year-to-date drop from $125.30 to $110.68 as of August 17, 2026, compares with more volatile moves in some high-growth sectors, while still representing a meaningful decline for a diversified healthcare name. Investors focused on capital preservation may see this as an opportunity to reassess entry points, especially given the stock’s history of playing a steady role in many balanced portfolios.
On the European trading line, the last close of EUR 95.08 and the subsequent quote of EUR 95.82, as reported for August 17 and August 18, 2026, respectively, highlight that the stock has been able to post short-term gains even within a broader negative year-to-date pattern. The table showing a year-to-date change of negative 10.77% for this euro-denominated line further illustrates how both currency and listing venue shape headline performance figures, reinforcing the need for investors to compare like-for-like measures when assessing their holdings.
Medical devices and diagnostics underpin the business
Behind the stock metrics, Abbott Laboratories’ business model remains heavily anchored in medical devices, diagnostics, and nutrition products. Company-profile summaries describe a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures, and markets a broad portfolio of medical products and services. These include cardiovascular and neuromodulation devices, diabetes-care technologies such as continuous glucose monitoring systems, and a large range of diagnostic testing solutions for both laboratory and point-of-care settings.
The diversified structure means that no single product line fully determines the company’s financial performance, but medical devices and diagnostics form a substantial part of revenue and profit generation. For investors, the key takeaway is that Abbott Laboratories’ stock reflects exposure to multiple growth drivers in global healthcare, from an aging population that supports demand for cardiovascular and chronic-disease treatments to rising awareness of preventative diagnostics.
Flagship glucose monitoring products
One of the most visible product families in Abbott Laboratories’ portfolio is its suite of continuous glucose monitoring systems for people living with diabetes. These devices are designed to provide near real-time glucose readings, often via sensors worn on the body that communicate with readers or mobile applications. Such systems aim to help patients and clinicians manage blood-sugar levels more effectively than traditional finger-stick testing alone, which can translate into better health outcomes and quality of life.
The growth of these glucose monitoring products has also positioned Abbott Laboratories as a significant player in the broader digital-health and remote-monitoring trend. As healthcare systems worldwide continue to invest in technologies that can reduce hospital admissions and enable at-home care, these devices can serve as a bridge between patients and providers. While individual product sales figures fall outside the scope of the latest market-data summaries, the prominence of this category in company profiles underscores its importance for the medium-term growth narrative underpinning Abbott Laboratories stock.
Closing view on Abbott Laboratories stock
From a market-data perspective, Abbott Laboratories stock currently trades at $110.68 as of the August 17, 2026 close in New York, down 11.7% from its 2026 starting level of $125.30. The consensus analyst price target of $118.67 sits above the latest closing price, signaling a measured degree of expected upside, while a dividend yield of 2.25% as cited for the euro-traded line reinforces the stock’s income component. For investors, the combination of a diversified healthcare business, a steady dividend, and a consensus view that still tilts positive provides a clear framework for evaluating the stock’s role in a broader portfolio.
Read more
Continuous glucose monitoring supports growth
Abbott Laboratories’ continuous glucose monitoring systems illustrate how the company leverages technology to expand its addressable market and deepen its relationship with patients and healthcare providers. By offering sensors and software that deliver frequent glucose readings and trend information, these products help users identify patterns, adjust therapy, and respond quickly to potential issues. In many markets, they have become a key tool for intensive diabetes management.
As reimbursement frameworks evolve and more healthcare systems recognize the clinical and economic benefits of better glucose control, adoption of such devices can contribute incrementally to Abbott Laboratories’ revenue. For shareholders, this segment exemplifies how innovation in medical devices can translate into recurring revenue streams, particularly when products are tied to consumable sensors and subscription-like digital services.
Latest price snapshot and investor angle
In the most recent pricing snapshot, Abbott Laboratories stock is reported with a closing price of $110.68 on August 17, 2026, on its New York listing, while a related quote shows EUR 95.08 as the last close and EUR 95.82 as a current price on a euro-denominated market on August 17 and August 18, 2026, respectively. The year-to-date performance figures of negative 11.7% for the U.S. line and negative 10.77% for the euro line highlight that the stock has lagged its opening levels for the year, even as it maintains a stable position in the low triple digits.
For investors weighing Abbott Laboratories against other healthcare names, the combination of a modest implied upside to the $118.67 consensus target, a 2.25% dividend yield, and diversified operations spanning diagnostics, medical devices, and nutrition may justify a closer look at how the stock fits within their risk tolerance and income needs. The key numerical markers - the $110.68 closing price as of August 17, 2026, the 11.7% year-to-date decline from $125.30, and the consensus target of $118.67 - provide a concrete framework for that assessment.
Fact box
Company: Abbott Laboratories Inc.
ISIN: US0028241000
Ticker: ABT
Exchange: NYSE
Price (as of August 17, 2026, 3:58 p.m. ET): $110.68 USD
Market cap: not specified in available data
Sector / Industry: Healthcare / Medical devices and diagnostics
Index membership: S&P 500
